PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma

被引：6

作者：

Zhong, Yu-Min ^{[1
,2
,3
]}

Yin, Kai ^{[2
,4
]}

Chen, Yu ^{[2
,3
]}

Xie, Zhi ^{[2
,3
]}

Lv, Zhi-Yi ^{[2
,3
]}

Yang, Jin-Ji ^{[2
]}

Yang, Xue-Ning ^{[2
]}

Zhou, Qing ^{[2
]}

Wang, Bin-Chao ^{[2
]}

Zhong, Wen-Zhao ^{[2
]}

Gao, Ling-Ling ^{[2
,4
]}

Zhou, Wen-Bin ^{[2
]}

Chen, Ji ^{[2
,4
]}

Tu, Hai-Yan ^{[2
]}

Liao, Ri-Qiang ^{[2
]}

Zhang, Dong-Kun ^{[5
]}

Zhang, Shui-Lian ^{[2
,3
]}

Lu, Dan-Xia ^{[2
,3
]}

Zheng, Hong-Bo ^{[6
]}

Zhang, Heng-Hui ^{[6
]}

Wu, Yi-Long ^{[2
]}

Zhang, Xu-Chao ^{[1
,2
,3
,4
]}

机构：

[1] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangdong Cardiovasc Inst, Guangzhou, Peoples R China

[2] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Canc Ctr, Guangzhou, Peoples R China

[3] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Med Res Ctr, Guangzhou, Peoples R China

[4] Southern Med Univ, Sch Clin Med 2, Guangzhou, Peoples R China

[5] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Thorac Surg, Guangzhou, Peoples R China

[6] Genecast Biotechnol, Dept Med Affairs, Wuxi, Peoples R China

来源：

FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷

基金：

中国国家自然科学基金;

关键词：

Lymphoepithelioma-like carcinoma; PD-1; PD-L1; inhibitors; LAG3; CELL LUNG-CANCER; NIVOLUMAB; CHEMOTHERAPY; EXPRESSION; THERAPY; PD-L1; EGFR; IMMUNOTHERAPY; PEMBROLIZUMAB; MUTATION;

D O I：

10.3389/fimmu.2022.951817

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Primary pulmonary lymphoepithelioma-like carcinoma (PLELC) is an Epstein-Barr virus (EBV)-related, rare subtype of non-small-cell lung cancer (NSCLC). Immune checkpoint inhibitors (ICI) show durable responses in advanced NSCLC. However, their effects and predictive biomarkers in PLELC remain poorly understood. We retrospectively analyzed the data of 48 metastatic PLELC patients treated with ICI. Pretreated paraffin-embedded specimens (n = 19) were stained for PD-1, PD-L1, LAG3, TIM3, CD3, CD4, CD8, CD68, FOXP3, and cytokeratin (CK) by multiple immunohistochemistry (mIHC). Next-generation sequencing was performed for 33 PLELC samples. Among patients treated with ICI monotherapy (n = 30), the objective response rate (ORR), disease control rate (DCR), median progression-free survival (mPFS), and overall survival (mOS) were 13.3%, 80.0%, 7.7 months, and 24.9 months, respectively. Patients with PD-L1 >= 1% showed a longer PFS (8.4 vs. 2.1 months, p = 0.015) relative to those with PD-L1 <1%. Among patients treated with ICI combination therapy (n = 18), ORR, DCR, mPFS, and mOS were 27.8%, 100.0%, 10.1 months, and 19.7 months, respectively. Patients with PD-L1 >= 1% showed a significantly superior OS than those with PD-L1 <1% (NA versus 11.7 months, p = 0.001). Among the 19 mIHC patients, those with high PD-1/PD-L1 and LAG3 expression showed a longer PFS (19.0 vs. 3.9 months, p = 0.003). ICI also showed promising efficacy for treating metastatic PLELC. PD-L1 may be both predictive of ICI treatment efficacy and prognostic for survival in PLELC. PD-1/PD-L1 combined with LAG3 may serve as a predictor of ICI treatment effectiveness in PLELC. Larger and prospective trials are warranted to validate both ICI activity and predictive biomarkers in PLELC.This study was partly presented as a poster at the IASLC 20th World Conference on Lung Cancer 2019, 7-10 September 2019, Barcelona, Spain.

引用

页数：12

共 50 条

[1] Tumor Microenvironment Is Associated with Efficacy of PD-1/PD-L1 Inhibitors in Patients with Primary Pulmonary Lymphoepithelioma-Like Cancer
Yin, K.
Xie, Z.
Lv, Z.
Yang, J.
Yang, X.
Zhou, Q.
Zhong, W.
Li, L.
Feng, H.
Guo, W.
Lu, D.
Chen, Y.
Yan, W.
Wu, Y.
Zhang, X.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S133 - S134
[2] PD-1/PD-L1 Inhibition Might be an Option for the Treatment of Advanced Primary Pulmonary Lymphoepithelioma-Like Carcinoma
Yin, K.
Xie, Z.
Yang, X.
Guo, W.
Chen, Y.
Yan, W.
Yang, J.
Zhou, Q.
Zhong, W.
Wu, Y.
Zhang, X.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S742 - S742
[3] Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma
Lee, Jiyun
La Choi, Yoon
Jung, Hyun Ae
Lee, Se-Hoon
Ahn, Jin Seok
Ahn, Myung-Ju
Park, Keunchil
Sun, Jong-Mu
EUROPEAN JOURNAL OF CANCER, 2020, 132 : 150 - 158
[4] Evaluation of PD-L1 biomarker for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatments for urothelial carcinoma patients: A meta-analysis
Rui, Xin
Gu, Ting-Ting
Pan, Hua-Feng
Zhang, Hui-Zhi
INTERNATIONAL IMMUNOPHARMACOLOGY, 2019, 67 : 378 - 385
[5] Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers
Duruisseaux, Michael
Rouquette, Isabelle
Adam, Julien
Cortot, Alexis
Cazes, Aurelie
Gibault, Laure
Damotte, Diane
Lantuejoul, Sylvie
ANNALES DE PATHOLOGIE, 2017, 37 (01) : 61 - 78
[6] PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
Yang, Tianrui
Kong, Ziren
Ma, Wenbin
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (02) : 546 - 553
[7] EBV-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma Response to PD-L1 Blockade
Narayanan, Anand
Knollmann, Friedrich D.
Walby, Julie Ann S.
Lim, Steffany
Gandara, David R.
Riess, Jonathan W.
CLINICAL LUNG CANCER, 2019, 20 (03) : E238 - E241
[8] PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
Li, Qian
Han, Jingjing
Yang, Yonglin
Chen, Yu
FRONTIERS IN IMMUNOLOGY, 2022, 13
[9] Exploring immune checkpoint inhibitors: Focus on PD-1/PD-L1 axis and beyond
Aden, Durre
Zaheer, Samreen
Sureka, Niti
Trisal, Monal
Chaurasia, Jai Kumar
Zaheer, Sufian
PATHOLOGY RESEARCH AND PRACTICE, 2025, 269
[10] Anti PD-1/PD-L1 Immune checkpoint inhibitors - addition - EML and EMLc
SELECTION AND USE OF ESSENTIAL MEDICINES: REPORT OF THE WHO EXPERT COMMITTEE ON SELECTION AND USE OF ESSENTIAL MEDICINES, 2019 (INCLUDING THE 21ST WHO MODEL LIST OF ESSENTIAL MEDICINES AND THE 7TH WHO MODEL LIST OF ESSENTIAL MEDICINES FOR CHILDREN), 2019, 1021 : 314 - 331

← 1 2 3 4 5 →